This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Altschul S.F., Gish W., Miller W., Myers E.W., Lipman D.J.: Basic local alignment search tool. J Mol Biol, 215, 403–410 (1990)AltschulS.F.GishW.MillerW.MyersE.W.LipmanD.J.Basic local alignment search toolJ Mol Biol215403410199010.1016/S0022-2836(05)80360-22231712Search in Google Scholar
Bairoch A., Apweiler R., Wu C.H., Barker W.C., Boeckmann B., Ferro S., Gasteiger E., Huang H., Lopez R., Magrane M. et al.: The Universal Protein Resource (UniProt). Nucleic Acids Res, 33, D154–159 (2005)BairochA.ApweilerR.WuC.H.BarkerW.C.BoeckmannB.FerroS.GasteigerE.HuangH.LopezR.MagraneM.The Universal Protein Resource (UniProt)Nucleic Acids Res33D154159200510.1093/nar/gki07054002415608167Search in Google Scholar
Biagini M., Spinsanti M., De Angelis G., Tomei S., Ferlenghi I., Scarselli M., Rigat F., Messuti N., Biolchi A., Muzzi A. et al.: Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined. Proc Natl Acad Sci USA, 113, 2714–2719 (2016)BiaginiM.SpinsantiM.De AngelisG.TomeiS.FerlenghiI.ScarselliM.RigatF.MessutiN.BiolchiA.MuzziA.Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determinedProc Natl Acad Sci USA11327142719201610.1073/pnas.1521142113479100926888286Search in Google Scholar
Bidmos F.A., Nadel S., Screaton G.R., Kroll J.S., Langford P.R.: Cross-Reactive Bactericidal Antimeningococcal Antibodies Can Be Isolated From Convalescing Invasive Meningococcal Disease Patients Using Reverse Vaccinology 2.0. Front Immunol, 9, 1621 (2018)BidmosF.A.NadelS.ScreatonG.R.KrollJ.S.LangfordP.R.Cross-Reactive Bactericidal Antimeningococcal Antibodies Can Be Isolated From Convalescing Invasive Meningococcal Disease Patients Using Reverse Vaccinology 2.0Front Immunol91621201810.3389/fimmu.2018.01621605503130061891Search in Google Scholar
Bidmos F.A., Siris S., Gladstone C.A., Langford P.R.: Bacterial Vaccine Antigen Discovery in the Reverse Vaccinology 2.0 Era: Progress and Challenges. Front Immunol, 9, 2315 (2018)BidmosF.A.SirisS.GladstoneC.A.LangfordP.R.Bacterial Vaccine Antigen Discovery in the Reverse Vaccinology 2.0 Era: Progress and ChallengesFront Immunol92315201810.3389/fimmu.2018.02315618797230349542Search in Google Scholar
Burton D.R.: Advancing an HIV vaccine; advancing vaccinology. Nat Rev Immunol, 19, 77–78 (2019)BurtonD.R.Advancing an HIV vaccine; advancing vaccinologyNat Rev Immunol197778201910.1038/s41577-018-0103-6642575230560910Search in Google Scholar
Bylsma L.C., Suh M., Movva N., Fryzek J.P., Nelson C.B.: Mortality Among US Infants and Children Under 5 Years of Age with Respiratory Syncytial Virus and Bronchiolitis: A Systematic Literature Review. J Infect Dis, 226, S267–S281 (2022)BylsmaL.C.SuhM.MovvaN.FryzekJ.P.NelsonC.B.Mortality Among US Infants and Children Under 5 Years of Age with Respiratory Syncytial Virus and Bronchiolitis: A Systematic Literature ReviewJ Infect Dis226S267S281202210.1093/infdis/jiac226937703435968871Search in Google Scholar
Christensen H., May M., Bowen L., Hickman M., Trotter C.L.: Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis, 10, 853–861 (2010)ChristensenH.MayM.BowenL.HickmanM.TrotterC.L.Meningococcal carriage by age: a systematic review and meta-analysisLancet Infect Dis10853861201010.1016/S1473-3099(10)70251-621075057Search in Google Scholar
Close B.E., Wilkinson J.M., Bohrer T.J., Goodwin C.P., Broom L.J., Colley K.J.: The polysialyltransferase ST8Sia II/STX: posttranslational processing and role of autopolysialylation in the polysialylation of neural cell adhesion molecule. Glycobiology, 11, 997–1008 (2001)CloseB.E.WilkinsonJ.M.BohrerT.J.GoodwinC.P.BroomL.J.ColleyK.J.The polysialyltransferase ST8Sia II/STX: posttranslational processing and role of autopolysialylation in the polysialylation of neural cell adhesion moleculeGlycobiology119971008200110.1093/glycob/11.11.99711744634Search in Google Scholar
Collins P.L., Melero J.A.: Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res, 162, 80–99 (2011)CollinsP.L.MeleroJ.A.Progress in understanding and controlling respiratory syncytial virus: still crazy after all these yearsVirus Res1628099201110.1016/j.virusres.2011.09.020322187721963675Search in Google Scholar
Ding C., Ma J., Dong Q., Liu Q.: Live bacterial vaccine vector and delivery strategies of heterologous antigen: A review. Immunol Lett, 197, 70–77 (2018)DingC.MaJ.DongQ.LiuQ.Live bacterial vaccine vector and delivery strategies of heterologous antigen: A reviewImmunol Lett1977077201810.1016/j.imlet.2018.03.00629550258Search in Google Scholar
Durrheim D.N.: Measles eradication-retreating is not an option. Lancet Infect Dis, 20, e138–e141 (2020)DurrheimD.N.Measles eradication-retreating is not an optionLancet Infect Dis20e138e141202010.1016/S1473-3099(20)30052-932197095Search in Google Scholar
Elveborg S., Monteil V.M., Mirazimi A.: Methods of Inactivation of Highly Pathogenic Viruses for Molecular, Serology or Vaccine Development Purposes. Pathogens, 11, (2022)ElveborgS.MonteilV.M.MirazimiA.Methods of Inactivation of Highly Pathogenic Viruses for Molecular, Serology or Vaccine Development PurposesPathogens11202210.3390/pathogens11020271887947635215213Search in Google Scholar
Emms D.M., Kelly S.: OrthoFinder: solving fundamental biases in whole genome comparisons dramatically improves orthogroup inference accuracy. Genome Biol, 16, 157 (2015)EmmsD.M.KellyS.OrthoFinder: solving fundamental biases in whole genome comparisons dramatically improves orthogroup inference accuracyGenome Biol16157201510.1186/s13059-015-0721-2453180426243257Search in Google Scholar
Fagnocchi L., Biolchi A., Ferlicca F., Boccadifuoco G., Brunelli B., Brier S., Norais N., Chiarot E., Bensi G., Kroll J.S. et al.: Transcriptional regulation of the nadA gene in Neisseria meningitidis impacts the prediction of coverage of a multicomponent meningococcal serogroup B vaccine. Infect Immun, 81, 560–569 (2013)FagnocchiL.BiolchiA.FerliccaF.BoccadifuocoG.BrunelliB.BrierS.NoraisN.ChiarotE.BensiG.KrollJ.S.Transcriptional regulation of the nadA gene in Neisseria meningitidis impacts the prediction of coverage of a multicomponent meningococcal serogroup B vaccineInfect Immun81560569201310.1128/IAI.01085-12355380423230289Search in Google Scholar
Gandhi A., Balmer P., York L.J.: Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba(R)). Postgrad Med, 128, 548–556 (2016)GandhiA.BalmerP.YorkL.J.Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba(R))Postgrad Med128548556201610.1080/00325481.2016.120323827467048Search in Google Scholar
Gilman M.S., Castellanos C.A., Chen M., Ngwuta J.O., Goodwin E., Moin S.M., Mas V., Melero J.A., Wright P.F., Graham B.S. et al.: Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Sci Immunol, 1, (2016)GilmanM.S.CastellanosC.A.ChenM.NgwutaJ.O.GoodwinE.MoinS.M.MasV.MeleroJ.A.WrightP.F.GrahamB.S.Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donorsSci Immunol1201610.1126/sciimmunol.aaj1879524481428111638Search in Google Scholar
Henderson D.A.: The eradication of smallpox-an overview of the past, present, and future. Vaccine, 29, D7–9 (2011)HendersonD.A.The eradication of smallpox-an overview of the past, present, and futureVaccine29D79201110.1016/j.vaccine.2011.06.08022188929Search in Google Scholar
Holst J., Oster P., Arnold R., Tatley M.V., Naess L.M., Aaberge I.S., Galloway Y., McNicholas A., O’Hallahan J., Rosenqvist E. et al.: Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum Vaccin Immunother, 9, 1241–1253 (2013)HolstJ.OsterP.ArnoldR.TatleyM.V.NaessL.M.AabergeI.S.GallowayY.McNicholasA.O’HallahanJ.RosenqvistE.Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the futureHum Vaccin Immunother912411253201310.4161/hv.24129390181323857274Search in Google Scholar
First-in-human clinical trial confirms novel HIV vaccine approach developed by IAVI and Scripps Research (https://www.iavi.org/news-resources/press-releases/2021/first-in-human-clinical-trial-confirms-novel-hiv-vaccine-approach-developed-by-iavi-and-scripps-research) (2021)First-in-human clinical trial confirms novel HIV vaccine approach developed by IAVI and Scripps Research(https://www.iavi.org/news-resources/press-releases/2021/first-in-human-clinical-trial-confirms-novel-hiv-vaccine-approach-developed-by-iavi-and-scripps-research)2021Search in Google Scholar
Johswich K.: Innate immune recognition and inflammation in Neisseria meningitidis infection. Pathog Dis, 75, (2017)JohswichK.Innate immune recognition and inflammation in Neisseria meningitidis infectionPathog Dis75201710.1093/femspd/ftx02228334203Search in Google Scholar
Kennedy D.A., Read A.F.: Why the evolution of vaccine resistance is less of a concern than the evolution of drug resistance. Proc Natl Acad Sci USA, 115, 12878–12886 (2018)KennedyD.A.ReadA.F.Why the evolution of vaccine resistance is less of a concern than the evolution of drug resistanceProc Natl Acad Sci USA1151287812886201810.1073/pnas.1717159115630497830559199Search in Google Scholar
Kim H., Webster R.G., Webby R.J.: Influenza Virus: Dealing with a Drifting and Shifting Pathogen. Viral Immunol, 31, 174–183 (2018)KimH.WebsterR.G.WebbyR.J.Influenza Virus: Dealing with a Drifting and Shifting PathogenViral Immunol31174183201810.1089/vim.2017.014129373086Search in Google Scholar
Klugman K.P., Black S.: Impact of existing vaccines in reducing antibiotic resistance: Primary and secondary effects. Proc Natl Acad Sci USA, 115, 12896–12901 (2018)KlugmanK.P.BlackS.Impact of existing vaccines in reducing antibiotic resistance: Primary and secondary effectsProc Natl Acad Sci USA1151289612901201810.1073/pnas.1721095115630497330559195Search in Google Scholar
Lauring A.S., Jones J.O., Andino R.: Rationalizing the development of live attenuated virus vaccines. Nat Biotechnol, 28, 573–579 (2010)LauringA.S.JonesJ.O.AndinoR.Rationalizing the development of live attenuated virus vaccinesNat Biotechnol28573579201010.1038/nbt.1635288379820531338Search in Google Scholar
Le Basle Y., Chennell P., Tokhadze N., Astier A., Sautou V.: Phsicochemical Stability of Monoclonal Antibodies: A Review. J Pharm Sci, 109, 169–190 (2020)Le BasleY.ChennellP.TokhadzeN.AstierA.SautouV.Phsicochemical Stability of Monoclonal Antibodies: A ReviewJ Pharm Sci109169190202010.1016/j.xphs.2019.08.00931465737Search in Google Scholar
Liao H.X., Lynch R., Zhou T., Gao F., Alam S.M., Boyd S.D., Fire A.Z., Roskin K.M., Schramm C.A., Zhang Z. et al.: Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature, 496, 469–476 (2013)LiaoH.X.LynchR.ZhouT.GaoF.AlamS.M.BoydS.D.FireA.Z.RoskinK.M.SchrammC.A.ZhangZ.Co-evolution of a broadly neutralizing HIV-1 antibody and founder virusNature496469476201310.1038/nature12053363784623552890Search in Google Scholar
Liguori A., Dello Iacono L., Maruggi G., Benucci B., Merola M., Lo Surdo P., Lopez-Sagaseta J., Pizza M., Malito E., Bottomley M.J.: NadA3 Structures Reveal Undecad Coiled Coils and LOX1 Binding Regions Competed by Meningococcus B Vaccine-Elicited Human Antibodies. MBio, 9, (2018)LiguoriA.Dello IaconoL.MaruggiG.BenucciB.MerolaM.Lo SurdoP.Lopez-SagasetaJ.PizzaM.MalitoE.BottomleyM.J.NadA3 Structures Reveal Undecad Coiled Coils and LOX1 Binding Regions Competed by Meningococcus B Vaccine-Elicited Human AntibodiesMBio9201810.1128/mBio.01914-18619153930327444Search in Google Scholar
Liljeroos L., Krzyzaniak M.A., Helenius A., Butcher S.J.: Architecture of respiratory syncytial virus revealed by electron cryotomography. Proc Natl Acad Sci USA, 110, 11133–11138 (2013)LiljeroosL.KrzyzaniakM.A.HeleniusA.ButcherS.J.Architecture of respiratory syncytial virus revealed by electron cryotomographyProc Natl Acad Sci USA1101113311138201310.1073/pnas.1309070110370398423776214Search in Google Scholar
Liu B., Zheng D., Zhou S., Chen L., Yang J.: VFDB 2022: a general classification scheme for bacterial virulence factors. Nucleic Acids Res, 50, D912–D917 (2022)LiuB.ZhengD.ZhouS.ChenL.YangJ.VFDB 2022: a general classification scheme for bacterial virulence factorsNucleic Acids Res50D912D917202210.1093/nar/gkab1107872818834850947Search in Google Scholar
Lu D.R., Tan Y.C., Kongpachith S., Cai X., Stein E.A., Lindstrom T.M., Sokolove J., Robinson W.H.: Identifying functional anti-Staphylococcus aureus antibodies by sequencing antibody repertoires of patient plasmablasts. Clin Immunol, 152, 77–89 (2014)LuD.R.TanY.C.KongpachithS.CaiX.SteinE.A.LindstromT.M.SokoloveJ.RobinsonW.H.Identifying functional anti-Staphylococcus aureus antibodies by sequencing antibody repertoires of patient plasmablastsClin Immunol1527789201410.1016/j.clim.2014.02.010406602324589749Search in Google Scholar
Luo H., Lin Y., Gao F., Zhang C.T., Zhang R.: DEG 10, an update of the database of essential genes that includes both protein-coding genes and noncoding genomic elements. Nucleic Acids Res, 42, D574–580 (2014)LuoH.LinY.GaoF.ZhangC.T.ZhangR.DEG 10, an update of the database of essential genes that includes both protein-coding genes and noncoding genomic elementsNucleic Acids Res42D574580201410.1093/nar/gkt1131396506024243843Search in Google Scholar
Martinson J.N.V., Walk S.T.: Escherichia coli Residency in the Gut of Healthy Human Adults. EcoSal Plus, 9, (2020)MartinsonJ.N.V.WalkS.T.Escherichia coli Residency in the Gut of Healthy Human AdultsEcoSal Plus9202010.1128/ecosalplus.ESP-0003-2020752333832978935Search in Google Scholar
Masignani V., Pizza M., Moxon E.R.: The Development of a Vaccine Against Meningococcus B Using Reverse Vaccinology. Front Immunol, 10, 751 (2019)MasignaniV.PizzaM.MoxonE.R.The Development of a Vaccine Against Meningococcus B Using Reverse VaccinologyFront Immunol10751201910.3389/fimmu.2019.00751647703431040844Search in Google Scholar
Mastrangelo P., Hegele R.G.: RSV fusion: time for a new model. Viruses, 5, 873–885 (2013)MastrangeloP.HegeleR.G.RSV fusion: time for a new modelViruses5873885201310.3390/v5030873370530123518574Search in Google Scholar
McAleer W.J., Buynak E.B., Maigetter R.Z., Wampler D.E., Miller W.J., Hilleman M.R.: Human hepatitis B vaccine from recombinant yeast. Nature, 307, 178–180 (1984)McAleerW.J.BuynakE.B.MaigetterR.Z.WamplerD.E.MillerW.J.HillemanM.R.Human hepatitis B vaccine from recombinant yeastNature307178180198410.1038/307178a06318124Search in Google Scholar
McArthur A.G., Waglechner N., Nizam F., Yan A., Azad M.A., Baylay A.J., Bhullar K., Canova M.J., De Pascale G., Ejim L. et al: The comprehensive antibiotic resistance database. Antimicrob Agents Chemother, 57, 3348–3357 (2013)McArthurA.G.WaglechnerN.NizamF.YanA.AzadM.A.BaylayA.J.BhullarK.CanovaM.J.De PascaleG.EjimL.The comprehensive antibiotic resistance databaseAntimicrob Agents Chemother5733483357201310.1128/AAC.00419-13369736023650175Search in Google Scholar
McLellan J.S., Chen M., Joyce M.G., Sastry M., Stewart-Jones G.B., Yang Y., Zhang B., Chen L., Srivatsan S., Zheng A. et al.: Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science, 342, 592–598 (2013)McLellanJ.S.ChenM.JoyceM.G.SastryM.Stewart-JonesG.B.YangY.ZhangB.ChenL.SrivatsanS.ZhengA.Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virusScience342592598201310.1126/science.1243283446186224179220Search in Google Scholar
McLellan J.S., Chen M., Leung S., Graepel K.W., Du X., Yang Y., Zhou T., Baxa U., Yasuda E., Beaumont T. et al.: Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science, 340, 1113–1117 (2013)McLellanJ.S.ChenM.LeungS.GraepelK.W.DuX.YangY.ZhouT.BaxaU.YasudaE.BeaumontT.Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibodyScience34011131117201310.1126/science.1234914445949823618766Search in Google Scholar
McLellan J.S., Ray W.C., Peeples M.E.: Structure and function of respiratory syncytial virus surface glycoproteins. Curr Top Microbiol Immunol, 372, 83–104 (2013)McLellanJ.S.RayW.C.PeeplesM.E.Structure and function of respiratory syncytial virus surface glycoproteinsCurr Top Microbiol Immunol37283104201310.1007/978-3-642-38919-1_4421164224362685Search in Google Scholar
Medini D., Donati C., Tettelin H., Masignani V., Rappuoli R.: The microbial pangenome. Curr Opin Genet Dev, 15, 589–594 (2005)MediniD.DonatiC.TettelinH.MasignaniV.RappuoliR.The microbial pangenomeCurr Opin Genet Dev15589594200510.1016/j.gde.2005.09.00616185861Search in Google Scholar
Moxon E.R.: Applications of molecular microbiology to vaccinology. Lancet, 350, 1240–1244 (1997)MoxonE.R.Applications of molecular microbiology to vaccinologyLancet35012401244199710.1016/S0140-6736(97)03259-59652581Search in Google Scholar
Mukhamedova M., Wrapp D., Shen C.H., Gilman M.S.A., Ruckwardt T.J., Schramm C.A., Ault L., Chang L., Derrien-Colemyn A., Lucas S.A.M. et al.: Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. Immunity, 54, 769–780 e766 (2021)MukhamedovaM.WrappD.ShenC.H.GilmanM.S.A.RuckwardtT.J.SchrammC.A.AultL.ChangL.Derrien-ColemynA.LucasS.A.M.Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responsesImmunity54769780e766202110.1016/j.immuni.2021.03.004809942233823129Search in Google Scholar
Naz K., Naz A., Ashraf S.T., Rizwan M., Ahmad J., Baumbach J., Ali A.: PanRV: Pangenome-reverse vaccinology approach for identifications of potential vaccine candidates in microbial pangenome. BMC Bioinformatics, 20, 123 (2019)NazK.NazA.AshrafS.T.RizwanM.AhmadJ.BaumbachJ.AliA.PanRV: Pangenome-reverse vaccinology approach for identifications of potential vaccine candidates in microbial pangenomeBMC Bioinformatics20123201910.1186/s12859-019-2713-9641945730871454Search in Google Scholar
Nesta B., Pizza M.: Vaccines Against Escherichia coli. Curr Top Microbiol Immunol, 416, 213–242 (2018)NestaB.PizzaM.Vaccines Against Escherichia coliCurr Top Microbiol Immunol416213242201810.1007/82_2018_11130062594Search in Google Scholar
O’Hagan D.T., Lodaya R.N., Lofano G.: The continued advance of vaccine adjuvants – ‘we can work it out’. Semin Immunol, 50, 101426 (2020)O’HaganD.T.LodayaR.N.LofanoG.The continued advance of vaccine adjuvants – ‘we can work it out’Semin Immunol50101426202010.1016/j.smim.2020.10142633257234Search in Google Scholar
Omersel J., Karas Kuzelicki N.: Vaccinomics and Adversomics in the Era of Precision Medicine: A Review Based on HBV, MMR, HPV, and COVID-19 Vaccines. J Clin Med, 9, (2020)OmerselJ.Karas KuzelickiN.Vaccinomics and Adversomics in the Era of Precision Medicine: A Review Based on HBV, MMR, HPV, and COVID-19 VaccinesJ Clin Med9202010.3390/jcm9113561769438833167413Search in Google Scholar
Osterloh A.: Vaccination against Bacterial Infections: Challenges, Progress, and New Approaches with a Focus on Intracellular Bacteria. Vaccines (Basel), 10, (2022)OsterlohA.Vaccination against Bacterial Infections: Challenges, Progress, and New Approaches with a Focus on Intracellular BacteriaVaccines (Basel)10202210.3390/vaccines10050751914473935632507Search in Google Scholar
Poland G.A., Kennedy R.B., McKinney B.A., Ovsyannikova I.G., Lambert N.D., Jacobson R.M., Oberg A.L.: Vaccinomics, adversomics, and the immune response network theory: individualized vaccinology in the 21st century. Semin Immunol, 25, 89–103 (2013)PolandG.A.KennedyR.B.McKinneyB.A.OvsyannikovaI.G.LambertN.D.JacobsonR.M.ObergA.L.Vaccinomics, adversomics, and the immune response network theory: individualized vaccinology in the 21st centurySemin Immunol2589103201310.1016/j.smim.2013.04.007375277323755893Search in Google Scholar
Poland G.A., Ovsyannikova I.G., Jacobson R.M.: Personalized vaccines: the emerging field of vaccinomics. Expert Opin Biol Ther, 8, 1659–1667 (2008)PolandG.A.OvsyannikovaI.G.JacobsonR.M.Personalized vaccines: the emerging field of vaccinomicsExpert Opin Biol Ther816591667200810.1517/14712598.8.11.1659283163418847302Search in Google Scholar
Poland G.A., Ovsyannikova I.G., Jacobson R.M.: Adversomics: the emerging field of vaccine adverse event immunogenetics. Pediatr Infect Dis J, 28, 431–432 (2009)PolandG.A.OvsyannikovaI.G.JacobsonR.M.Adversomics: the emerging field of vaccine adverse event immunogeneticsPediatr Infect Dis J28431432200910.1097/INF.0b013e3181a6a511284313619395950Search in Google Scholar
Pulendran B., P S.A., O’Hagan D.T.: Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov, 20, 454–475 (2021)PulendranB.PS.A.O’HaganD.T.Emerging concepts in the science of vaccine adjuvantsNat Rev Drug Discov20454475202110.1038/s41573-021-00163-y802378533824489Search in Google Scholar
Rappuoli R.: Reverse vaccinology. Curr Opin Microbiol, 3, 445–450 (2000)RappuoliR.Reverse vaccinologyCurr Opin Microbiol3445450200010.1016/S1369-5274(00)00119-311050440Search in Google Scholar
Rappuoli R., Bottomley M.J., D’Oro U., Finco O., De Gregorio E.:Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design. J Exp Med, 213, 469–481 (2016)RappuoliR.BottomleyM.J.D’OroU.FincoO.De GregorioE.Reverse vaccinology 2.0: Human immunology instructs vaccine antigen designJ Exp Med213469481201610.1084/jem.20151960482165027022144Search in Google Scholar
Rodrigues C.M.C., Plotkin S.A.: Impact of Vaccines; Health, Economic and Social Perspectives. Front Microbiol, 11, 1526 (2020)RodriguesC.M.C.PlotkinS.A.Impact of Vaccines; Health, Economic and Social PerspectivesFront Microbiol111526202010.3389/fmicb.2020.01526737195632760367Search in Google Scholar
Scarselli M., Giuliani M.M., Adu-Bobie J., Pizza M., Rappuoli R.: The impact of genomics on vaccine design. Trends Biotechnol, 23, 84–91 (2005)ScarselliM.GiulianiM.M.Adu-BobieJ.PizzaM.RappuoliR.The impact of genomics on vaccine designTrends Biotechnol238491200510.1016/j.tibtech.2004.12.00815661345Search in Google Scholar
Schneider M.C., Prosser B.E., Caesar J.J., Kugelberg E., Li S., Zhang Q., Quoraishi S., Lovett J.E., Deane J.E., Sim R.B. et al.: Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature, 458, 890–893 (2009)SchneiderM.C.ProsserB.E.CaesarJ.J.KugelbergE.LiS.ZhangQ.QuoraishiS.LovettJ.E.DeaneJ.E.SimR.B.Neisseria meningitidis recruits factor H using protein mimicry of host carbohydratesNature458890893200910.1038/nature07769267027819225461Search in Google Scholar
Serruto D., Spadafina T., Ciucchi L., Lewis L.A., Ram S., Tontini M., Santini L., Biolchi A., Seib K.L., Giuliani M.M. et al.: Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci USA, 107, 3770–3775 (2010)SerrutoD.SpadafinaT.CiucchiL.LewisL.A.RamS.TontiniM.SantiniL.BiolchiA.SeibK.L.GiulianiM.M.Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humansProc Natl Acad Sci USA10737703775201010.1073/pnas.0915162107284051420133713Search in Google Scholar
Shaw C.A., Ciarlet M., Cooper B.W., Dionigi L., Keith P., O’Brien K.B., Rafie-Kolpin M., Dormitzer P.R.: The path to an RSV vaccine. Curr Opin Virol, 3, 332–342 (2013)ShawC.A.CiarletM.CooperB.W.DionigiL.KeithP.O’BrienK.B.Rafie-KolpinM.DormitzerP.R.The path to an RSV vaccineCurr Opin Virol3332342201310.21775/9781910190036.17Search in Google Scholar
Shi S., Zhu H., Xia X., Liang Z., Ma X., Sun B.: Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity. Vaccine, 37, 3167–3178 (2019)ShiS.ZhuH.XiaX.LiangZ.MaX.SunB.Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticityVaccine3731673178201910.1016/j.vaccine.2019.04.05531047671Search in Google Scholar
Siris S.: Identification of pneumococcal vaccine antigens using Reverse Vaccinology 2.0. Thesis or dissertation. London: Imperial College London; 2021.SirisS.Identification of pneumococcal vaccine antigens using Reverse Vaccinology 2.0Thesis or dissertation.LondonImperial College London2021Search in Google Scholar
Spadiut O., Capone S., Krainer F., Glieder A., Herwig C.: Microbials for the production of monoclonal antibodies and antibody fragments. Trends Biotechnol, 32, 54–60 (2014)SpadiutO.CaponeS.KrainerF.GliederA.HerwigC.Microbials for the production of monoclonal antibodies and antibody fragmentsTrends Biotechnol325460201410.1016/j.tibtech.2013.10.002390653724183828Search in Google Scholar
Stephens D.S., Greenwood B., Brandtzaeg P.: Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet, 369, 2196–2210 (2007)StephensD.S.GreenwoodB.BrandtzaegP.Epidemic meningitis, meningococcaemia, and Neisseria meningitidisLancet36921962210200710.1016/S0140-6736(07)61016-217604802Search in Google Scholar
Tatusov R.L., Koonin E.V., Lipman D.J.: A genomic perspective on protein families. Science, 278, 631–637 (1997)TatusovR.L.KooninE.V.LipmanD.J.A genomic perspective on protein familiesScience278631637199710.1126/science.278.5338.6319381173Search in Google Scholar
Tettelin H., Masignani V., Cieslewicz M.J., Donati C., Medini D., Ward N.L., Angiuoli S.V., Crabtree J., Jones A.L., Durkin A.S. et al.: Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial “pangenome”. Proc Natl Acad Sci USA, 102, 13950–13955 (2005)TettelinH.MasignaniV.CieslewiczM.J.DonatiC.MediniD.WardN.L.AngiuoliS.V.CrabtreeJ.JonesA.L.DurkinA.S.Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial “pangenome”Proc Natl Acad Sci USA1021395013955200510.1073/pnas.0506758102121683416172379Search in Google Scholar
The: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics, 102, 531–537 (1998)The: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infantsThe IMpact-RSV Study GroupPediatrics102531537199810.1542/peds.102.3.531Search in Google Scholar
Thwaites C.L., Loan H.T.: Eradication of tetanus. Br Med Bull, 116, 69–77 (2015)ThwaitesC.L.LoanH.T.Eradication of tetanusBr Med Bull1166977201510.1093/bmb/ldv044467400626598719Search in Google Scholar
Tong L., Huang S., Zheng C., Zhang Y., Chen Z.: Refractory Mycoplasma pneumoniae Pneumonia in Children: Early Recognition and Management. J Clin Med, 11 (2022)TongL.HuangS.ZhengC.ZhangY.ChenZ.Refractory Mycoplasma pneumoniae Pneumonia in Children: Early Recognition and ManagementJ Clin Med11202210.3390/jcm11102824914410335628949Search in Google Scholar
van de Berg D., Kis Z., Behmer C.F., Samnuan K., Blakney A.K., Kontoravdi C., Shattock R., Shah N.: Quality by design modelling to support rapid RNA vaccine production against emerging infectious diseases. NPJ Vaccines, 6, 65 (2021)van de BergD.KisZ.BehmerC.F.SamnuanK.BlakneyA.K.KontoravdiC.ShattockR.ShahN.Quality by design modelling to support rapid RNA vaccine production against emerging infectious diseasesNPJ Vaccines665202110.1038/s41541-021-00322-7808519933927197Search in Google Scholar
Vilela Rodrigues T.C., Jaiswal A.K., de Sarom A., de Castro Oliveira L., Freire Oliveira C.J., Ghosh P., Tiwari S., Miranda F.M., de Jesus Benevides L., Ariston de Carvalho Azevedo V. et al.: Reverse vaccinology and subtractive genomics reveal new therapeutic targets against Mycoplasma pneumoniae: a causative agent of pneumonia. R Soc Open Sci, 6, 190907 (2019)Vilela RodriguesT.C.JaiswalA.K.de SaromA.de Castro OliveiraL.Freire OliveiraC.J.GhoshP.TiwariS.MirandaF.M.de Jesus BenevidesL.Ariston de Carvalho AzevedoV.Reverse vaccinology and subtractive genomics reveal new therapeutic targets against Mycoplasma pneumoniae: a causative agent of pneumoniaR Soc Open Sci6190907201910.1098/rsos.190907668957231417766Search in Google Scholar
Whitaker J.A., Ovsyannikova I.G., Poland G.A.: Adversomics: a new paradigm for vaccine safety and design. Expert Rev Vaccines, 14, 935–947 (2015)WhitakerJ.A.OvsyannikovaI.G.PolandG.A.Adversomics: a new paradigm for vaccine safety and designExpert Rev Vaccines14935947201510.1586/14760584.2015.1038249463080425937189Search in Google Scholar
Wu X., Zhang Z., Schramm C.A., Joyce M.G., Kwon Y.D., Zhou T., Sheng Z., Zhang B., O’Dell S., McKee K. et al.: Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection. Cell, 161, 470–485 (2015)WuX.ZhangZ.SchrammC.A.JoyceM.G.KwonY.D.ZhouT.ShengZ.ZhangB.O’DellS.McKeeK.Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 InfectionCell161470485201510.1016/j.cell.2015.03.004470617825865483Search in Google Scholar
Yao L., Sun T.: Glycyrrhizin administration ameliorates Streptococcus aureus-induced acute lung injury. Int Immunopharmacol, 70, 504–511 (2019)YaoL.SunT.Glycyrrhizin administration ameliorates Streptococcus aureus-induced acute lung injuryInt Immunopharmacol70504511201910.1016/j.intimp.2019.02.04630884430Search in Google Scholar
Yokoyama W.M., Christensen M., Santos G.D., Miller D., Ho J., Wu T., Dziegelewski M., Neethling F.A.: Production of monoclonal antibodies. Curr Protoc Immunol, 102, 251–2529 (2013)YokoyamaW.M.ChristensenM.SantosG.D.MillerD.HoJ.WuT.DziegelewskiM.NeethlingF.A.Production of monoclonal antibodiesCurr Protoc Immunol1022512529201310.1002/0471142735.im0205s10224510488Search in Google Scholar
Zhou C.E., Smith J., Lam M., Zemla A., Dyer M.D., Slezak T.: MvirDB--a microbial database of protein toxins, virulence factors and antibiotic resistance genes for bio-defence applications. Nucleic Acids Res, 35, D391–394 (2007)ZhouC.E.SmithJ.LamM.ZemlaA.DyerM.D.SlezakT.MvirDB--a microbial database of protein toxins, virulence factors and antibiotic resistance genes for bio-defence applicationsNucleic Acids Res35D391394200710.1093/nar/gkl791166977217090593Search in Google Scholar
Zhou T., Georgiev I., Wu X., Yang Z.Y., Dai K., Finzi A., Kwon Y.D., Scheid J.F., Shi W., Xu L. et al.: Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science, 329, 811–817 (2010)ZhouT.GeorgievI.WuX.YangZ.Y.DaiK.FinziA.KwonY.D.ScheidJ.F.ShiW.XuL.Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01Science329811817201010.1126/science.1192819298135420616231Search in Google Scholar